Max Sight Group Holdings Limited Overview
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Employees at year end (headcount) | — | 64 | 78 | 64 | 47 |
Max Sight Group is a micro-cap Hong Kong consumer-services company that for more than three decades has operated a network of automatic identity-document (ID) photo booths under the "Max Sight Photo" brand, positioned in metro stations, ID and visa application centres, universities, hospitals and shopping malls. Since October 2021 it has diversified into primary-care medical services through a small network of general-practice clinics branded "Max Medical", which in FY2025 overtook photography as the larger revenue line. The photo-booth franchise — historically high-margin and supplied by ME Group (Photo-Me) — is in structural decline as Hong Kong's Immigration Department digitises ID-photo capture through Personal Document Submission Kiosks and visa processes move online, and following the April 2025 expiry of a major government-site service contract. With revenue down 45% from its FY2023 post-COVID peak, rising losses and thin equity, the company was acquired in July 2026 by entrepreneur Li Xiangpu, whose plans beyond maintaining the existing businesses and listing remain undisclosed.
Company's own description
In its FY2025 Annual Report and FY2026 interim filings, the company describes itself as principally engaged in (i) providing photography services through automatic ID photo booths in Hong Kong (and, until 2025, Guangdong Province), and (ii) providing medical services by operating medical centres in Hong Kong, with a focus on general practice — primary care for acute illness and chronic disease management, routine health screenings, vaccinations and specialist referrals (IRA H1 2026). The company's website characterises it as a leading automatic ID photo-booth operator in Hong Kong and Guangdong, with a service promise summarised as precise validation and simple photography, backed by an "unconditional guarantee" of a free retake or full refund if a customer is dissatisfied with a photo (company website, accessed October 2026).
The medical business is described as offering physical-examination plans, vaccination services, outreach doctor services, and sales of therapeutic services and wellness merchandise, alongside community medical benefit programmes (company website).
Business model and revenue model
| Revenue stream | Model | Recognition | FY2025 revenue (HKD Mn) | Share of total |
|---|---|---|---|---|
| ID photo booth services (retail) | Pay-per-use self-service kiosks; cash and smart-card (Octopus-type) payment; site licences paid to landlords on fixed, revenue-share or higher-of basis | Point in time | Part of 21.190 | 47.6% (photography total) |
| Sale of photo strips / consumables to an institutional customer | Product sale — replaced a service contract at government ID/visa sites after it matured in April 2025 | Point in time | Part of 21.190 | (included above) |
| Medical consultation and related services | Fee-for-service GP consultations; vaccinations; health screening; medical cards via network agents; HK Government Elderly Health Care Vouchers | Point in time | 23.305 | 52.4% |
Source: ARA FY2025 note 2; IRA H1 2026 notes 4 and 12.
The revenue model is 100% transactional — no subscription or licensing revenue is disclosed. All revenue is recognised at a point in time (ARA FY2025). No single customer exceeded 10% of revenue in FY2024, FY2025 or H1 2026 (ARA FY2025; IRA H1 2026).
Value-chain position
Photography: Max Sight sits at the operator/retail end of the value chain. It does not manufacture booths; booths and consumables have historically been sourced from ME Group International plc (formerly Photo-Me International plc), a relationship dating from 1993 and formalised in a Master Supply Agreement dated 4 August 2023 covering FY2023–FY2025 with annual caps of HK$1 M for booths and HK$3 M for consumables (AR 2023, AR 2025). Its key upstream dependency is landlords/licensors (MTR stations, government buildings, malls, universities) that grant booth sites.
Medical: The Group owns and operates clinic premises and engages doctors partly through consultancy companies that are also minority shareholders in clinic-holding subsidiaries (Echo Bay Consultant Company Limited holds 19% of Speed Dragon Development Limited; Mingway Health Limited holds 20% of Wealthy Dragon Development Limited) and are paid a fixed monthly fee plus profit share (Company announcement, 25 Sep 2026).
Customer types and end-markets
| End-market | Customer type | Key demand drivers |
|---|---|---|
| ID photography (Hong Kong) | General public needing passport, HKID, visa, travel permit, student and licence photos | Document renewal cycles; travel demand; immigration schemes (e.g., Top Talent Pass Scheme from 2022–23); government document digitisation (negative) |
| ID photography (Guangdong) | General public | Largely displaced by PRC online applications with digital photos and face recognition (ARA FY2025) — operations wound down by end-2025 |
| Primary care (Hong Kong) | Walk-in patients, medical-card holders via network agents, elderly using healthcare vouchers | Seasonal influenza; HK Primary Healthcare Blueprint; Hospital Authority fee reform effective 1 Jan 2026 |
Independent characterisation
Max Sight is best understood as a sub-scale, family-built, cash-generative-at-peak niche operator that has been caught between two structural shifts: (1) the digital substitution of physical ID photos, which is eroding a historically high-margin core; and (2) an unsuccessful attempt to scale a diversification into primary care, which, while stable at roughly HK$22–23 M of revenue, generates segment margins in the mid-single digits and has not expanded beyond its existing clinics since 2023 because "no suitable project was identified" (ARA FY2025). The July 2026 sale of 75% of the company at HK$0.0875 per share — a 22% discount to the prior closing price but a 376% premium to book value — is consistent with a transaction priced substantially on the value of the GEM listing platform itself (JA 27 Jul 2026). Post-transaction, the strategic direction is effectively a blank page pending the new controller's review.
Strategy
Stated strategy (legacy management, AR 2025 and IRA H1 2026)
The pre-transaction strategy, paraphrased from the FY2025 Chairman's Statement and MD&A, rested on four themes:
-
Defend photography share through quality and coverage — management repeatedly asserted that substantial ID-photo demand will persist in Hong Kong and that service quality and site coverage drive share; resources were reallocated to booth hardware/software upgrades, booth decoration, staff training, advertising, and site-by-site profitability reviews with relocations (ARA FY2025).
-
Explore digital adaptation — meetings with partners and vendors to upgrade IT infrastructure and assess delivering digital ID photos through existing booths (ARA FY2025).
-
Build medical into a recurring-income pillar — expand the medical team, scope of services and clinic network; obtain clinic licences under the Private Healthcare Facilities Ordinance (Cap. 633); position for the Primary Healthcare Blueprint and the Hospital Authority fee reform effective 1 Jan 2026 (ARA FY2025).
-
Diversify and broaden revenue base — continued research into new business opportunities (generic, no specifics).
Initiatives register (last 24 months)
| Date | Initiative | Status / outcome | Source |
|---|---|---|---|
| Ongoing 2024–2026 | Booth upgrade and marketing programme (IPO proceeds: HK$4.24 M allocated; HK$2.44 M used by 30 Jun 2026) | In progress; unutilised HK$1.80 M to be used by 31 Dec 2026 | IRA H1 2026 |
| Ongoing 2024–2026 | Medical business development (HK$5.65 M allocated; HK$0.65 M used by 30 Jun 2026) | Largely unexecuted; HK$4.99 M unutilised | IRA H1 2026 |
| FY2025 | Feasibility of digital ID photo output via booths | Under assessment; no launch disclosed | ARA FY2025 |
| Dec 2025 | Discontinue Guangdong booth expansion; concentrate on Hong Kong | Completed (subsidiary deregistered) | ARA FY2025 |
| Dec 2025 | Discontinue planned medical laboratory expansion | Completed | ARA FY2025 |
| FY2024–FY2025 | Cost reduction (staff, directors' remuneration) | Admin costs −18% FY2025; −23% H1 2026 YoY | ARA FY2025; IRA H1 2026 |
| 8 Aug 2025 | Workforce Diversity Policy | Adopted | AR 2025 |
| 25 Sep 2026 | Extension of doctor service agreements (Echo Bay, Mingway) to 31 Dec 2028 with increased annual caps | Executed | Announcement 25 Sep 2026 |
New controller's stated intentions (JA 27 Jul 2026)
The offeror stated that the Group will continue its existing photography and medical businesses after the offer and maintain the GEM listing; that it will review operations and financial position to devise plans and explore opportunities; that it has no intention to discontinue employees (other than board changes) or redeploy fixed assets outside the ordinary course, while reserving the right to make changes after its review. Mr. Li characterised the investment as a new venture into the Group's principal businesses. Given Mr. Li's F&B background and the new executive director's PRC capital-markets compliance experience, investors should watch for new business injections or acquisitions — none has been announced as of 11 October 2026.
Medium-term targets / guidance
No medium-term financial targets, revenue guidance or margin targets have been published by either legacy or current management. ESG/sustainability targets: none quantitative disclosed in reviewed filings.
Products & Services
Photography Services
| Offering | Description | Key capabilities | Target customer | Launch / latest | Pricing model | Source |
|---|---|---|---|---|---|---|
| Max Sight Photo automatic ID photo booths (Hong Kong) | Self-service digital booths producing ID photos to multiple official specifications | Multiple ID specifications (passport, HKID, visa, permits); high-end print quality; validation against specifications; smart-card payment | General public | Brand operating since 1989; digital booths since c. late 1990s–2003 | Per-session retail price (specific tariffs not disclosed in filings) | Company website; IRA H1 2026; AR 2025 |
| "Unconditional guarantee" | Free retake or full refund on return of unsatisfactory photos | Service-quality differentiator | General public | Ongoing | Included | Company website |
| Photo strip sales to institutional customer | After April 2025 expiry of a service contract at multiple ID/visa application centres, Group retained the customer by selling strips (consumables) instead of providing full service | Supply of consumables | Government-linked ID/visa centres | From April 2025 | Per-strip product pricing, materially lower unit value than prior service model | IRA H1 2026; ARA FY2025 |
| Automatic photographic studio services at government ID offices | 24-month tender won Feb 2023, effective 1 Mar 2023, for a HK government authority responsible for issuing ID documents | Installed booth/studio services in government offices | HK government authority | 2023–2025 | Tender contract (value not disclosed) | AR 2023 |
| 名仕富美 booths (Guangdong) | ID photo booths in Guangdong province | As above | PRC public | 2005–2025 | Per-session | AR 2023; AR 2025 |
| Digital ID photo services via booths (under study) | Feasibility assessment of offering digital ID photo outputs through existing booths | Digital file delivery | Public applying online | Under evaluation (FY2025) | — | ARA FY2025 |
Medical Services ("Max Medical 名仕醫療")
| Offering | Description | Target customer | Launch | Pricing model | Source |
|---|---|---|---|---|---|
| General practice consultations | Diagnosis and treatment of acute illness, chronic disease management | Walk-in patients; medical-card members | Oct 2021 | Fee-for-service; medical card settlement via network agents within ~60 days | IRA H1 2026 |
| Vaccinations (incl. seasonal influenza) | Vaccine administration | General public, elderly | 2021 onward | Fee-based; government vouchers accepted | ARA FY2025; company website |
| Health screening / physical exam plans | Multiple-choice physical examination packages | Individuals, corporates | — | Package pricing (not disclosed) | Company website |
| Specialist referrals | Referral to specialists | Patients | — | Included in consultation | IRA H1 2026 |
| Outreach doctor services | Doctor visits outside clinics | — | — | — | Company website |
| Therapeutic services and wellness merchandise | Retail of therapeutic/wellness products | Patients | — | Retail | Company website |
| Community medical benefit programme | CSR programme | Community | — | Subsidised | Company website |
Clinic locations disclosed: Wong Tai Sin (Max Medical Service Limited; doctor services by Echo Bay / Dr. Li Ka Hei Calvin) and Sham Shui Po (Wealthy Dragon; doctor services by Mingway / Dr. Tse Ming) (announcement 25 Sep 2026). A new medical centre tenancy was signed in FY2023 (AR 2023). The total number of clinics is not explicitly stated in the filings reviewed.
Abandoned initiatives: Medical laboratory expansion (discontinued Dec 2025 due to price competition from Mainland labs) and new clinic acquisitions (none identified in FY2025 or H1 2026) (ARA FY2025; IRA H1 2026).
Financial Narrative
Income statement
Sources and notes: FY2024–FY2025 from ARA FY2025. FY2022–FY2023 revenue, cost of services, gross profit, admin, finance costs, tax and attributable result from AR 2023. FY2023 and FY2022 operating profit and PBT are (derived) from AR 2023 line items (FY2023: GP 26.905 + other income 0.584 − other net losses 0.049 − admin 18.273 − ROU impairment 0.077; FY2022 uses an ROU impairment of approx. HK$2.1 M from the 7 Mar 2023 profit warning). FY2021 and FY2022 net loss (approx.) from profit warnings (FY2021 approx. HK$7.7 M; FY2022 approx. HK$12.4 M). FY2023 net profit approx. HK$8.0 M (derived), consistent with the positive profit alert indicating not less than HK$8 M. EPS for FY2022–FY2023 (derived) on 800 M shares. FY2023 DPS = interim HK$0.00375 + special HK$0.005625. EBITDA is post-HKFRS 16 (includes right-of-use depreciation, so it overstates cash earnings).
Margins and growth
Revenue CAGR FY2021–FY2025: approx. +20.7% per year (distorted by the COVID trough base). Revenue CAGR FY2023–FY2025: approx. −25.5% per year (derived). FY2021 growth uses FY2020 revenue of approx. HK$19.98 M (profit warning 4 Mar 2021; TipRanks).
Interim trend: notes and sources
Source: IRA H1 2025; IRA H1 2026.
Balance sheet
Sources: ARA FY2025; AR 2023; IRA H1 2025 (opening equity 1 Jan 2024). FY2022 and FY2023 total assets (derived) from reported equity and gearing ratio (total liabilities ÷ total assets of 51.5% and 48.7%). No goodwill or intangibles appear on the FY2024–FY2025 statements of financial position.
At 30 June 2026: total assets HK$29.455 M; cash HK$9.206 M; lease liabilities HK$12.086 M; total equity HK$12.551 M (attributable HK$11.444 M); net current assets HK$2.455 M (IRA H1 2026).
Cash flow
Interim operating cash flow (table 6.3) shows a sharp deterioration from HK$6.3 M (H1 2024) to HK$1.4 M (H1 2026); after lease principal and interest payments of HK$4.7 M in H1 2026, lease-adjusted free cash flow was approximately −HK$3.3 M for the half (derived from IRA H1 2026). Sources: AR 2023; ARA FY2025; IRA H1 2025; IRA H1 2026.
Ratios
Current, quick and gearing ratios as reported (AR 2023; ARA FY2025). Other ratios (derived). ROIC and cash conversion cycle: not meaningfully computable from disclosed data (no invested-capital disclosure; business is largely cash-settled with receivables of HK$1.8 M at FY2025, i.e., roughly 15 days of revenue — derived). Net debt/EBITDA FY2025 approx. 0.2x including leases (derived).
Commentary on trends, inflections and drivers
Revenue. The five-year arc is defined by three phases. FY2020–FY2022 was a COVID trough in which travel-document demand collapsed and the Group launched medical services as a hedge, lifting FY2022 revenue 49% on the first full year of clinic operations (AR 2022 summary). FY2023 was an exceptional reopening spike — photography revenue rose 178% as quarantine was lifted and travel resumed, and a two-year government-site tender began in March 2023 (AR 2023). FY2024–FY2026 is a structural decline: photography revenue fell 51% in FY2025 and another 53% in H1 2026 as the government contract matured (April 2025), the Immigration Department's PDSK kiosks absorbed demand, e-visas reduced physical photo needs, and immigration-scheme tailwinds (JoyYou card from 2022; Top Talent Pass Scheme) proved less durable than expected (ARA FY2025).
Margins. Gross margin peaked at 33.5% in FY2023 and has compressed to 25.2% in H1 2026 because photography carries a higher margin than medical and its share of the mix has fallen (ARA FY2025). Variable lease payments to booth landlords fell from HK$17.2 M (FY2024) to HK$4.6 M (FY2025), showing that much of the photography cost base was revenue-linked, which cushioned but did not prevent margin erosion (ARA FY2025 note 7).
Costs. Management cut administrative expenses by 18% in FY2025 and a further 23% year-on-year in H1 2026, mainly through staff reductions (headcount down from 78 to 45 in 30 months) and lower directors' remuneration (ARA FY2025; IRA H1 2026). Head-office costs remain disproportionate: HK$8.7 M of corporate expenses in FY2025 against total segment profit of HK$4.6 M — the listed-company overhead alone exceeds what the operations earn.
Balance sheet. The company carried no bank debt at end-2024 and end-2025, but equity has nearly halved from HK$28.7 M (attributable, 1 Jan 2024) to HK$11.4 M (30 Jun 2026) through a combination of losses and HK$9.3 M of special dividends paid in 2024–2025 out of share premium and distributable reserves. Distributable reserves of the company were just HK$165k at end-2025 (AR 2025), effectively precluding further dividends. Cash has fallen from HK$25.7 M (end-2023) to HK$9.2 M (mid-2026), while lease obligations (HK$12.1 M) now exceed cash — the group has swung from net cash to modest net debt on a lease-inclusive basis.
Inflection. H1 2026 is the first period in which both segments declined simultaneously (medical revenue −10.7% due to an absent winter influenza season and a new price-competitive clinic near one of the Group's sites) (IRA H1 2026). At the current burn rate, liquidity is adequate for perhaps 18–24 months absent action, but the trajectory explains the founders' decision to exit.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products / services | Status |
|---|---|---|---|
Photography services — Hong Kong | Max Sight Limited and related entities; booth network across MTR stations, ID/visa centres, malls, universities, hospitals | Self-service ID photo booths; sale of photo strips to an institutional customer at ID/visa centres | Core, declining |
Photography services — Mainland China | Guangzhou Max Sight Photo Company Limited ("名仕富美" brand) | ID photo booths in Guangdong | Effectively discontinued; revenue HK$9k in FY2025, nil in H1 2026; subsidiary deregistered in FY2025 |
Medical services — Hong Kong | Max Medical Service Limited, Max Sight Healthcare Management Limited, Speed Dragon Development Limited (81%), Wealthy Dragon Development Limited (80%), Max Medical Service (NOP Clinic) Limited | GP consultations, vaccinations, health screening, specialist referrals, wellness merchandise | Largest segment from FY2025 |
Photography | 21.181 | 0.009 | 21.190 |
Medical | 23.305 | 0 | 23.305 |
Total | 44.486 | 0.009 | 44.495 |
Revenue by Segment
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Photography services Hong Kong (HKD Mn) | 18.97 | 22.42 | 63.83 | 42.498 | 21.181 |
Photography services Mainland China (HKD Mn) | 1.34 | 0.94 | 1.21 | 0.917 | 0.009 |
Medical services Hong Kong (HKD Mn) | 0.642 | 7.891 | 15.179 | 22.831 | 23.305 |
Total revenue (HKD Mn) | 20.953 | 31.253 | 80.218 | 66.246 | 44.495 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment | FY2024 | FY2025 |
|---|---|---|
Photography Hong Kong segment profit (HKD Mn) | 12.397 | 3.112 |
Photography Mainland China segment profit (HKD Mn) | 0.145 | -0.316 |
Medical Hong Kong segment profit (HKD Mn) | 1.167 | 1.758 |
Total reportable segment profit (HKD Mn) | 13.709 | 4.554 |
Head office and corporate expenses (HKD Mn) | -12.977 | -8.690 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Photography HK segment margin (%) | — | — | — | 29.2 | 14.7 |
Medical HK segment margin (%) | — | — | — | 5.1 | 7.5 |
Photography HK revenue growth YoY (%) | — | 18.2 | 184.7 | -33.4 | -50.2 |
Medical HK revenue growth YoY (%) | — | 1,129.1 | 92.4 | 50.4 | 2.1 |
Photography (all) share of revenue (%) | 96.9 | 74.8 | 81.1 | 65.5 | 47.6 |
Medical share of revenue (%) | 3.1 | 25.2 | 18.9 | 34.5 | 52.4 |
Revenue by Segment (Half-Yearly)
| Segment | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|
Photography HK revenue (HKD Mn) | 22.887 | 14.255 | 6.646 |
Photography Mainland revenue (HKD Mn) | 0.554 | 0.009 | 0 |
Medical HK revenue (HKD Mn) | 11.133 | 11.884 | 10.609 |
Photography HK segment profit (HKD Mn) | 6.908 | 3.964 | 0.290 |
Medical HK segment profit (HKD Mn) | 0.456 | 1.282 | 0.778 |
Group Entities
| Entity | Jurisdiction | Function | Ownership | Source |
|---|---|---|---|---|
Max Sight Limited | Hong Kong | Original photo-booth operator (since 1989) | 100% (indirect) | AR 2023/2025 |
Fullwise International Limited | Not disclosed in reviewed docs | Group holding/operating entity | — | AR 2023 |
Guangzhou Max Sight Photo Company Limited | PRC | Guangdong booth operator | Deregistered FY2025 (inferred from deregistration loss and nil Mainland activity) | AR 2023; ARA FY2025 |
Max Medical Service Limited | Hong Kong | Medical services; Wong Tai Sin clinic | 100% | Announcement 25 Sep 2026 |
Max Sight Healthcare Management Limited | Hong Kong | Clinic management services | 100% | Announcement 25 Sep 2026 |
Speed Dragon Development Limited | Hong Kong | Clinic-holding subsidiary | 81% (Echo Bay holds 19%) | Announcement 25 Sep 2026 |
Wealthy Dragon Development Limited | Hong Kong | Sham Shui Po clinic | 80% (Mingway holds 20%) | Announcement 25 Sep 2026 |
Max Medical Service (NOP Clinic) Limited | Hong Kong | Medical (formerly MV Asset Management Limited) | Not disclosed in reviewed docs | AR 2025 |
“—” = not publicly disclosed.
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 20.953 | 31.253 | 80.218 | 66.246 | 44.495 |
Cost of services (HKD Mn) | — | 26.175 | 53.313 | 45.969 | 32.426 |
Gross profit (HKD Mn) | — | 5.078 | 26.905 | 20.277 | 12.069 |
Administrative expenses (HKD Mn) | — | 16.596 | 18.273 | 19.219 | 15.691 |
Operating profit / loss from operations (HKD Mn) | — | -12.10 | 9.09 | 1.434 | -3.147 |
Depreciation total (HKD Mn) | — | — | — | 9.938 | 10.300 |
EBITDA incl. ROU depreciation (HKD Mn) | — | — | — | 11.372 | 7.153 |
Finance costs (HKD Mn) | — | 0.454 | 0.659 | 0.702 | 1.053 |
Profit / loss before tax (HKD Mn) | — | -12.55 | 8.43 | 0.732 | -4.200 |
Income tax (expense negative) (HKD Mn) | — | 0.120 | -0.412 | -0.262 | 0.237 |
Net profit / loss for year (HKD Mn) | -7.7 | -12.4 | 8.0 | 0.470 | -3.963 |
Attributable to owners (HKD Mn) | — | -11.518 | 7.658 | -0.399 | -4.598 |
Basic and diluted EPS (HK cents) | — | -1.44 | 0.96 | -0.05 | -0.57 |
Dividends per share declared for the year (HK cents) | — | 0 | 0.9375 | 0.60 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 4.9 | 49.2 | 156.7 | -17.4 | -32.8 |
Gross margin (%) | — | 16.25 | 33.54 | 30.6 | 27.1 |
Operating margin (%) | — | -38.7 | 11.3 | 2.2 | -7.1 |
EBITDA margin (%) | — | — | — | 17.2 | 16.1 |
Net margin (%) | -36.7 | -39.7 | 10.0 | 0.7 | -8.9 |
Cash Flow and Margin Analysis (%)
| Metric | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|
Revenue (HKD Mn) | 34.574 | 26.148 | 17.255 |
Gross profit (HKD Mn) | 10.839 | 8.218 | 4.347 |
Gross margin (%) | 31.35 | 31.43 | 25.19 |
Administrative expenses (HKD Mn) | 10.188 | 8.753 | 6.744 |
Profit / loss from operations (HKD Mn) | 0.739 | -0.152 | -2.335 |
Profit / loss attributable to owners (HKD Mn) | -0.199 | -1.138 | -3.255 |
Net cash from operating activities (HKD Mn) | 6.292 | 4.684 | 1.400 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (HKD Mn) | 46.8 | 54.5 | 45.810 | 35.898 |
Cash and bank balances (HKD Mn) | 21.699 | 25.669 | 21.320 | 12.902 |
Restricted bank deposit (HKD Mn) | 5.0 | 5.0 | 0 | 0 |
Bank loans (HKD Mn) | 1.0 | 1.0 | 0 | 0 |
Lease liabilities current (HKD Mn) | — | — | 6.819 | 7.949 |
Lease liabilities non-current (HKD Mn) | — | — | 8.073 | 6.549 |
Total lease liabilities (HKD Mn) | — | — | 14.892 | 14.498 |
Net debt incl. leases (HKD Mn, negative = net cash) | — | — | -6.428 | 1.596 |
Total equity (HKD Mn) | 22.714 | 27.945 | 24.163 | 15.462 |
Equity attributable to owners (HKD Mn) | — | 28.686 | 24.035 | 14.699 |
Goodwill and intangibles (HKD Mn) | — | — | 0 | 0 |
Net current assets (HKD Mn) | — | — | 13.629 | 5.021 |
Right-of-use assets (HKD Mn) | — | — | 13.928 | 13.574 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Capital expenditure on PP&E (HKD Mn) | — | 3.000 | 0.572 | 1.715 | 0.016 |
Dividends paid (HKD Mn) | — | 0 | 3.000 | 4.500 | 4.800 |
Share buybacks (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE on average total equity (%) | — | 31.7 | 1.8 | -19.9 |
ROE attributable on average attributable equity (%) | — | — | -1.5 | -23.7 |
ROA on average total assets (%) | — | 15.8 | 0.9 | -9.7 |
Current ratio (x) | 1.92 | 1.95 | 2.04 | 1.37 |
Quick ratio (x) | 1.87 | 1.87 | 1.92 | 1.24 |
Gearing total liabilities / total assets (%) | 51.5 | 48.7 | 47.3 | 56.9 |
Lease liabilities to equity (x) | — | — | 0.62 | 0.94 |
Interest coverage EBIT / finance costs (x) | — | 13.8 | 2.0 | -3.0 |
Asset turnover (x) | — | 1.58 | 1.32 | 1.09 |
Revenue by Region
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hong Kong (HKD Mn) | 19.62 | 30.31 | 79.01 | 65.329 | 44.486 |
Mainland China (HKD Mn) | 1.34 | 0.94 | 1.21 | 0.917 | 0.009 |
Region Margins & Growth (%)
| Region | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Hong Kong revenue growth (%) | 54.5 | 160.7 | -17.3 | -31.9 |
Mainland China revenue growth (%) | -29.9 | 28.7 | -24.2 | -99.0 |
Share Price History
| Date | Price (HKD) | Context | Source |
|---|---|---|---|
28 Feb 2018 | 0.31 (offer) / 0.36 (day-1 close) | IPO | Press release 28 Feb 2018 |
~25 Apr 2024 | 0.084 | Pre-FY2024 results | Yahoo Finance snapshot |
~22 Oct 2025 | approx. 0.097 | Market cap HK$77.6 M on Simply Wall St | Simply Wall St (derived) |
16 Feb 2026 | 0.093 | Six-month closing low | JA 27 Jul 2026 |
5 May 2026 | 0.146 | Six-month closing high | JA 27 Jul 2026 |
24 Jul 2026 | 0.112 | Last trading day before SPA | JA 27 Jul 2026 |
Offer price | 0.0875 | SPA and mandatory offer price | JA 27 Jul 2026 |
~5 Oct 2026 | 0.33 | Approx. +177% year-to-date per MarketScreener | MarketScreener; Yahoo Finance |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market cap | approx. HK$264 M | 800 M × 0.33 |
Enterprise value (incl. leases) | approx. HK$267 M | 264 − cash 9.2 + leases 12.1 |
TTM revenue | HK$35.6 M | FY2025 44.495 − H1'25 26.148 + H1'26 17.255 |
TTM attributable net loss | −HK$6.7 M | −4.598 + 1.138 − 3.255 |
P/E | Not meaningful (loss) | — |
EV/Sales | approx. 7.5x | — |
EV/EBITDA (post-HKFRS 16) | approx. 61x | TTM EBITDA approx. HK$4.4 M (derived) |
P/B | approx. 23x | Attributable equity HK$11.4 M |
Offer-implied valuation | HK$70 M equity; approx. 4.8x NAV | JA 27 Jul 2026 |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
DPS declared in respect of year (HK cents) | 0 | 0.9375 | 0.60 | 0 |
Total dividends declared (HKD Mn) | 0 | 7.5 | 4.8 | 0 |
Analyst Conclusions
Management guidance and consensus
No quantitative guidance has been issued by legacy or new management, and there is no sell-side consensus. The legacy board's last outlook (FY2025 AR) was "cautiously optimistic," premised on persistent ID-photo demand and policy tailwinds in primary care. The new controller has committed only to continuing existing businesses, maintaining the listing and conducting a review (JA 27 Jul 2026).
Bull case
-
Platform optionality under a funded new owner. CWT paid HK$52.5 M in cash with no borrowings, and the chairman has multi-country F&B and tech investment experience; asset injections or acquisitions could transform scale relative to a HK$12.6 M equity base (JA 27 Jul 2026).
-
Medical segment stabilisation plus policy tailwind. Medical revenue held at HK$22–23 M through FY2024–FY2025 and doctor agreements are locked in to 2028 with rising caps; a normal flu season and HA fee reform could restore growth (announcement 25 Sep 2026; IRA H1 2026).
-
Lean cost base post-restructuring. Headcount down 42% since 2023 and admin costs down sharply; a cleaner, Hong Kong-only operation with no bank debt lowers break-even (IRA H1 2026).
Bear case
-
Core business in terminal decline. Photography HK segment profit is down 96% in two years and the drivers (PDSK, e-visas, expired contract) are structural, not cyclical (IRA H1 2026).
-
Valuation detached from fundamentals. At approx. 23x book and 7.5x sales for a loss-making company, the share price embeds substantial speculative value, nearly 4x the price the controller paid weeks earlier, on a sub-minimum free float (derived; JA 2 Oct 2026).
-
Cash runway and governance discontinuity. Cash HK$9.2 M against lease obligations of HK$12.1 M and an H1 2026 lease-adjusted cash burn of approx. HK$3.3 M; entire experienced management departed, with no CEO named (IRA H1 2026; announcement 5 Oct 2026).
Catalysts and monitorables (next 12 months)
| Catalyst | Expected timing | What to watch |
|---|---|---|
| Public float restoration (placing down by CWT) and Stock Exchange waiver | Q4 2026 | Placing price vs. market; risk of suspension |
| CEO appointment and executive team composition | Q4 2026 | Operating continuity of booth and clinic businesses |
| Offeror's strategic review outcome; any acquisition or asset injection | Q4 2026 – 2027 | Related-party nature, valuation, any equity issuance/dilution |
| Use of remaining HK$7.35 M IPO proceeds by 31 Dec 2026 | By Dec 2026 | Possible further reallocation |
| ME Group supply relationship post-MSA expiry | 2026–2027 | Renewal, alternative suppliers |
| FY2026 profit warning / results | Mar 2027 | Revenue trajectory; second-half influenza season impact on medical |
| Auditor continuity (RSM Hong Kong) and any going-concern commentary | Mar 2027 | Audit opinion |
Analyst verdict
Max Sight Group is no longer primarily an operating story; it is a change-of-control story wrapped around a shrinking legacy business. The fundamentals are unambiguous. The photo-booth franchise that sustained the company for over three decades is being hollowed out by government digitisation — Hong Kong photography segment profit fell from HK$12.4 million in FY2024 to under HK$0.3 million in the first half of 2026 — and the medical diversification, though steady at roughly HK$22–23 million of revenue, is too small and too low-margin to carry a listed-company overhead that by itself exceeds total segment earnings. Equity has more than halved in 30 months through losses and special dividends, distributable reserves are exhausted, and lease obligations now exceed cash.
Against this backdrop, the founders' decision to sell 75% at HK$0.0875 per share — a discount to market but nearly five times book value — is rational, and it crystallised what the platform was worth to a strategic buyer. The subsequent re-rating to around HK$0.33 is not supported by any disclosed operating improvement; it reflects speculation about what Mr. Li Xiangpu will do with a GEM-listed vehicle, amplified by a public float that has slipped below the regulatory minimum.
For fundamental investors, the risk-reward at current prices is unfavourable: the downside if no value-accretive transaction materialises is substantial, with intrinsic value anchored closer to the offer price and net assets than to the current quote. For special-situation investors, the critical near-term variables are the terms of any float-restoring placement, the identity and track record of incoming management, and whether any injected business is acquired at arm's-length value without heavy dilution. Until the new controller articulates a credible plan, Max Sight should be regarded as a high-risk, event-driven shell-adjacent situation rather than an investable operating franchise.
Primary sources referenced
-
Max Sight Group — Annual Results Announcement FY2025 (23 Mar 2026), hkexnews.hk
-
Max Sight Group — Annual Report 2025 (2 Apr 2026) and Annual Report 2023 (28 Mar 2024), maxsightgroup.com
-
Max Sight Group — Interim Results Announcements H1 2025 (8 Aug 2025) and H1 2026 (31 Aug 2026)
-
Joint Announcement — SPA and Mandatory Unconditional Cash Offer (27 Jul 2026)
-
Joint Announcement — Close of Offer, Results and Public Float (2 Oct 2026)
-
Announcement — Continuing Connected Transactions: Echo Bay and Mingway Service Agreements (25 Sep 2026)
-
Announcement — Resignation and Appointment of Directors (5 Oct 2026); company website board biographies
-
Profit warnings dated 4 Mar 2021, 4 Mar 2022, 7 Mar 2023, 14 Mar 2025 (hkexnews.hk)
-
Company press releases on IPO (15, 27 and 28 Feb 2018)
-
Third-party data: MarketScreener (segment history FY2021–FY2023, price), Yahoo Finance (price, TTM), Simply Wall St (Oct 2025 ownership/market cap), TipRanks (revenue history, peer list), Morningstar (company profile)
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Education | Age |
|---|---|---|---|---|---|
Mr. Li Xiangpu (李相璞) | Executive Director, Chairman; Chair of Nomination Committee; member of Remuneration Committee; authorised representative | 5 Oct 2026 | Entrepreneur with close to 15 years' experience in VC, IT and internet businesses; since 2017 invested in/managed F&B businesses (fast-food chains, restaurants, foodstuff supply chains) in HK, PRC, Indonesia, Vietnam and Korea; previously Testing Manager at Nokia (2008–2012) and Senior Engineer at Lucent Technologies (2004–2008); sole director and ultimate controller of CWT Limited | B.Eng. electronic science and technology (2004) and M.Eng. (2011), Beijing University of Posts and Telecommunications | 44 (per JA 27 Jul 2026) |
Mr. Yang Lichao (楊立超) | Executive Director | 5 Oct 2026 | 15+ years in finance management and compliance; former strategy director and board secretary of Shanghai Fukong Interactive Entertainment (former SSE: 600634, delisted Jul 2021); compliance director of Shanghai Banxiaoyao Technology since Jul 2023; prior finance roles at several PRC industrial groups | Bachelor of Management, Anhui University of Technology (2008); SSE board secretary qualifications | — |
Mr. Zhong Jin (鍾錦) | Lead INED; Chair of Remuneration Committee; member of Audit and Nomination Committees | 5 Oct 2026 | 40+ years in banking/finance; China Construction Bank Sichuan roles (1985–2002); China CINDA Asset Management office director (2002–2011); MD then chairman of China CINDA (Hong Kong) Holdings (2011–2019); INED of Luzhou Bank (01983) since Nov 2020 | PhD Finance, Southwestern University of Finance and Economics (2006); senior economist | — |
Mr. Pang Peter Chun Ming (彭浚銘) | INED; Chair of Audit Committee; member of Remuneration Committee | 5 Oct 2026 | 20+ years in audit and finance; Ernst & Young (US/HK); BOCI Asia corporate finance; Deutsche Bank; CFO of Renjian Antong, Pa Shun Pharmaceutical (00574) and Fuli Peridot Mining; currently CFO of Neo-Concept International (NASDAQ: NCI) and INED of Zuoli Kechuang (06866) | BA Economics UC Berkeley; MAcc USC; California CPA; CFA | — |
Ms. Sze Tak On (施得安) | INED; member of Audit and Nomination Committees | 5 Oct 2026 | Financial controller (since 2004) and company secretary of Century Legend (Holdings) (00079); INED of A.Plus Group (01841), Prosperous Industrial (01731), China Starch (03838) | MCF, Hong Kong Polytechnic University; HKICPA, FCCA, HKCGI | — |
“—” = not publicly disclosed.
Board of Directors — Mr. Chan Wing Chai, Jamson
| Name | Role | Tenure | Notes |
|---|---|---|---|
Mr. Chan Wing Chai, Jamson | Chairman, ED | 26 Jan 2017 – 5 Oct 2026 (Group director since 1989) | Age 79 (AR 2025); founder; expected to remain director of subsidiaries post-deal (JA 27 Jul 2026) |
Mr. Chan Tien Kay, Timmy | CEO, ED, compliance officer | 26 Jan 2017 – 5 Oct 2026 | Age 52; Queensland solicitor; son of Jamson Chan; expected to remain director of subsidiaries |
Dr. Chan Wing Lok, Brian | ED; chief medical executive | 6 Sep 2021 – 23 Mar 2026 | Age 61; ex-ED of Town Health International (3886); resigned due to personal health (AR 2025) |
Mr. Riccardo Costi | NED | 26 Jan 2017 – 5 Oct 2026 | Age 81; associate interested in Dedem S.p.A. (European photo-booth operator) — declared competing interest |
Ms. Wong Shin Yee, Freda | NED | 8 Nov 2024 – 5 Oct 2026 | Age 55; managing partner, Sunny Fortune Capital |
Mr. Ngai James | INED, Lead INED, Audit and Remuneration chair | 8 Feb 2018 – 5 Oct 2026 | CPA; chairman of Le Saunda Holdings (0738) |
Mr. Hui Chi Kwan | INED | 8 Feb 2018 – 5 Oct 2026 | Solicitor; INED of Le Saunda |
Mr. Kwok Tsun Wa | INED | 8 Feb 2018 – 5 Oct 2026 | Insurance veteran (Lombard, HSBC Non-Life, Marsh HK) |
Directors' Remuneration
| Metric | FY2024 | FY2025 |
|---|---|---|
Key management remuneration total (HKD Mn) | 7.528 | 6.921 |
Of which short-term benefits (HKD Mn) | 7.409 | 6.813 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
23 May 2024 | Zhu Yulin appointed finance director | Replaced Wong Chi Hong's finance role (AR 2025) |
8 Nov 2024 | Wong Shin Yee, Freda appointed NED | Addressed single-gender board commitment by end-2024 (AR 2023) |
8 Aug 2025 | Wong and Hui added to Nomination Committee; Workforce Diversity Policy adopted | Governance enhancements (AR 2025) |
23 Mar 2026 | Dr. Brian Chan resigns as ED | Personal health (AR 2025) |
23 Sep 2026 | Board resolves to appoint Li, Yang, Zhong, Pang, Sze effective 5 Oct 2026 | Post-takeover reconstitution |
5 Oct 2026 | All seven legacy directors resign; Li appointed chairman; Zhong lead INED | Required under SPA (JA 27 Jul 2026) |
Major Shareholders
| Holder | Shares | % | Source |
|---|---|---|---|
CWT Limited (99% XDQX ZZRS Ltd / XPFF Trust; 1% BTY PT Ltd — all ultimately Li Xiangpu and family) | 601,144,000 | 75.14 | JA 2 Oct 2026 |
Public shareholders | 198,856,000 | 24.86 | JA 2 Oct 2026 |
Total | 800,000,000 | 100.00 | — |
Competitive Landscape
Competitors by Segment
| Segment | Competitor / substitute | Type | Positioning vs. Max Sight |
|---|---|---|---|
ID photography | HK Immigration Department Personal Document Submission Kiosks (PDSK) | Government digital substitute (free digital photo capture during submission) | Most damaging substitute; company attributes approx. 19% same-site strip-volume decline in H1 2026 to PDSK |
ID photography | Traditional photo studios (notably near visa application centres) | Fragmented SMEs | Persistent price competition cited every period since 2024 |
ID photography | Smartphone/e-visa digital photo submission | Behavioural substitute | Structural demand erosion |
ID photography | Other HK booth operators | Not identified in filings | Company claims leading booth operator position |
ID photography (global) | ME Group International plc (Photo-Me) | Global booth operator/manufacturer; former 13.75% shareholder and supplier | Not a direct HK competitor; strategic supplier |
ID photography (Europe) | Dedem S.p.A. | European booth operator linked to former NED Riccardo Costi's associate | Declared potentially competing business; no HK overlap disclosed |
Primary care | Town Health International Medical Group (HKEX: 3886) | Listed HK medical network | Far larger network; Dr. Brian Chan's former employer |
Primary care | UMP Healthcare Holdings (HKEX: 722) | Listed HK corporate healthcare network | Larger scale, corporate-contract focus |
Primary care | Human Health Holdings (HKEX: 1419) | Listed HK GP and specialist clinics | Larger GP network |
Primary care | Modern Healthcare Technology Holdings; Miricor Enterprises; Sino-Life Group; Anxian Yuan China (listed peers per TipRanks peer screen) | Listed small-cap HK health/consumer services | Similar micro-cap scale |
Primary care | Hospital Authority general out-patient clinics | Public provider | Lower-cost alternative; fee reform from 2026 may shift non-urgent demand to private sector |
Primary care | Independent private GPs (incl. a new price-competitive clinic near one Group site) | Fragmented | Cited as driver of H1 2026 medical revenue decline |
Competitor Detail
| Metric | Max Sight (FY2025) |
|---|---|
Revenue | HK$44.5 M |
Revenue growth | −32.8% |
Gross margin | 27.1% |
Net margin | −8.9% |
Recent Developments
--



